Stevanato Group S.p.A. Ordinary Shares (STVN)

FairStock Score: 38/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach Stevanato as a healthcare supplier: it makes drug containment and delivery products, plus diagnostic and engineering solutions, for biopharma customers. In the second quarter of 2026, revenue was $302.0M and net income was $23.0M, a 7.60% net margin. That is a real profit, but FairStock’s calculations show ROE of 9.13% and ROCE of 5.45%—scarcely the returns of a wide-moat compounder. The balance sheet is a comfort: debt-to-equity of 0.29 and an Altman Z-Score of 3.39. Liquidity is less comforting: trailing free cash flow was negative $30.7M, for a FCF yield of -0.7%. As of the 2026-10-13 close, the price was $19.26, giving FairStock a P/E of 34.39, P/B of 2.92, EV/EBITDA of 19.53, and PEG of 6.15. FairStock’s Graham Number is $8.45, meaning the price carries a -127.93% margin of safety—far above asset-based value. The FairStock Score is 38/100, and the Lynch category is none because only 0 years of filed results exist. Piotroski is 6/9, respectable but not exceptional. Growth may come from biopharma demand, but the current multiple already assumes much better profitability and cash generation. I would need evidence that returns on capital and free cash flow are improving before calling this a bargain.

In plain English: Stevanato Group makes packaging and delivery products for medicines and diagnostics, such as syringes, vials, and testing supplies. The business is profitable and has modest debt, but it is spending more cash than it brings in and earns only moderate returns. At the recent close, the shares look expensive relative to its earnings and net assets.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer